CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE (clindamycin phosphate)
Clindamycin phosphate is a topical medication that treats acne vulgaris. It is used for patients with skin breakouts, though physicians must carefully consider its use due to the risk of severe side effects like bloody diarrhea and colitis. This medication helps manage acne when a healthcare provider determines it is the most suitable option among available therapies.
How CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE Works
The specific way clindamycin phosphate works to improve acne is currently unknown. While the medication is used to manage this condition, the exact biological mechanism of action has not been established.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2017-04-20
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE Approval History
What CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE Treats
1 indicationsCLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Acne Vulgaris
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04469075 | 19-342 | Ph 2 | active not recruiting | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields |
| NCT04321070 | CLPL 1907 | Ph 1 | completed | Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris |
| NCT00616330 | CBC-302-602-622467 | Ph 3 | completed | Vaginal Infection Study |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE FDA Label Details
Indications & Usage
FDA Label (PDF)CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is indicated for the treatment of Acne Vulgaris.
Track CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment